Skip to main content

Table 2 Absolute overestimation in cumulative recrudescence by Kaplan-Meier (K-M) method compared to Cumulative Incidence Function (CIF) in simulation study I (n = 500 subjects)

From: Evaluating antimalarial efficacy in single-armed and comparative drug trials using competing risk survival analysis: a simulation study

  Median absolute overestimation [IQR; Range]
5% recrudescence Observed proportion of new infectionsa Day 28 Day 42 Day 63
  < 10% NI 3.8% [1.0–6.6] 0.00% [0.00–0.00; Range:0.00–0.01] 0.02% [0.01–0.02; Range:0.00–0.06] 0.06% [0.05–0.07; Range:0.01–0.16]
 10–20% NI 17.0% [12.8–19.8] 0.00% [0.00–0.01; Range:0.00–0.02] 0.08% [0.07–0.10; Range:0.01–0.22] 0.31% [0.26–0.36; Range:0.13–0.55]
 20–40% NI 31.2% [25.0–37.8] 0.01% [0.00–0.01; Range:0.00–0.04] 0.18% [0.14–0.22; Range:0.04–0.42] 0.63% [0.54–0.73; Range:0.28–1.20]
 40 + % NI 43.0% [40.0–50.0] 0.01% [0.01–0.02; Range:0.00–0.06] 0.28% [0.23–0.34; Range:0.09–0.60] 0.94% [0.82–1.09; Range:0.32–1.75]
10% recrudescence
  < 10% NI 3.6% [1.2–6.2] 0.00% [0.00–0.00; Range:0.00–0.02] 0.03% [0.02–0.04; Range:0.00–0.11] 0.12% [0.10–0.15; Range:0.03–0.27]
 10–20% NI 16.4% [10.8–19.8] 0.01% [0.00–0.01; Range:0.00–0.05] 0.17% [0.14–0.21; Range:0.05–0.36] 0.60% [0.53–0.68; Range:0.26–0.96]
 20–40% NI 30.0% [24.4–36.2] 0.02% [0.01–0.02; Range:0.00–0.07] 0.36% [0.31–0.42; Range:0.13–0.89] 1.22% [1.09–1.37; Range:0.69–2.04]
 40 + % NI 42.0% [40.0–48.0] 0.03% [0.02–0.04; Range:0.00–0.08] 0.56% [0.48–0.65; Range:0.28–1.07] 1.90% [1.69–2.11; Range:1.18–3.13]
15% recrudescence
  < 10% NI 3.4% [1.0–6.2] 0.00% [0.00–0.00; Range:0.00–0.02] 0.05% [0.03–0.07; Range:0.00–0.16] 0.18% [0.14–0.22; Range:0.05–0.46]
 10–20% NI 16.0% [10.0–19.8] 0.01% [0.01–0.02; Range:0.00–0.06] 0.26% [0.22–0.31; Range:0.10–0.54] 0.92% [0.80–1.03; Range:0.46–1.50]
 20–40% NI 28.8% [23.0–36.6] 0.02% [0.02–0.03; Range:0.00–0.08] 0.54% [0.46–0.62; Range:0.25–1.02] 1.81% [1.64–2.01; Range:1.11–3.03]
 40 + % NI 41.0% [40.0–45.8] 0.04% [0.03–0.06; Range:0.00–0.14] 0.88% [0.77–1.00; Range:0.44–1.60] 2.91% [2.64–3.18; Range:1.69–4.30]
  1. aValues presented are median [Range]; NI = New infections